We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IRTC:NASDAQiRhythm Holdings, Inc. Analysis

Data as of 2026-06-17 - not real-time

$106.55

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

iRhythm Holdings (IRTC) is trading at $106.55, well above its DCF fair value of $57, indicating significant overvaluation despite a recent bullish MACD crossover and an RSI of 39 that suggests the stock is approaching oversold territory. Revenue growth remains robust at 25.7% YoY and gross margins sit near 71%, but operating margins are negative and the company posted a trailing EPS of -$0.85, underscoring ongoing profitability challenges. The balance sheet is strained, with a debt‑to‑equity ratio exceeding 450 and total debt surpassing cash reserves, while the forward PE of 101 dwarfs the industry average of 24.6. Technical signals are mixed: the price is below its 20‑day, 50‑day, and 200‑day SMAs, confirming a bearish trend, yet the MACD histogram turned positive and the stock is perched just above the $101.75 support level. A recent cybersecurity incident involving third‑party applications was disclosed, but management asserts no material impact on operations, adding a layer of reputational risk. Overall, the stock’s high volatility (43% 30‑day) and modest beta (≈0.6) reflect a volatile but not overly market‑correlated profile. Given the overvaluation, weak earnings, and elevated debt, the upside appears limited while downside risk remains pronounced. Investors should weigh the short‑term technical bounce potential against the long‑term structural headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD crossover and near‑oversold RSI suggest a possible short‑term rebound
  • Price is close to a defined support level at $101.75
  • Cybersecurity incident deemed non‑material but adds uncertainty

Medium Term

1–3 years
Cautious
Model confidence: 8/10

Key Factors

  • Persistent negative operating earnings and high debt‑to‑equity ratio
  • Stock price far exceeds DCF fair value and industry multiples
  • Bearish trend indicated by price below all major moving averages

Long Term

> 3 years
Cautious
Model confidence: 9/10

Key Factors

  • Fundamental weaknesses: negative margins, high leverage, and extreme forward PE
  • Regulatory and cybersecurity risks could impair growth prospects
  • Valuation gap suggests limited upside potential over the long horizon

Key Metrics & Analysis

Financial Health

Revenue Growth25.70%
Profit Margin-3.53%
P/E Ratio101.4
ROE-22.42%
ROA-1.15%
Debt/Equity452.39
P/B Ratio21.7
Op. Cash Flow$62.6M
Free Cash Flow$57.0M
Industry P/E24.6

Technical Analysis

TrendBearish
RSI39.9
Support$101.75
Resistance$123.15
MA 20$111.60
MA 50$116.74
MA 200$150.85
MACDBullish
VolumeStable
Fear & Greed Index91.32

Valuation

Fair Value$57.21
Target Price$178.93
Upside/Downside67.93%
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.61
Volatility43.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.